Endothelial nitric oxide synthase (eNOS) produces nitric oxide (NO), which is involved in various physiological functions of the cardiovascular system. eNOS is activated by dephosphorylation at Thr495 and phosphorylation at Ser1177. Inhibition of Rho-kinase, an effector of the small GTPase RhoA, leads to activation of Akt/PKB, which phosphorylates eNOS at Ser1177 and thereby promotes NO production. However, little is known about the effects of Rho-kinase on phosphorylation of Thr495. We here found that the constitutively active form of Rho-kinase phosphorylated eNOS at Thr495 in vitro. Expression of the constitutively active form of RhoA or Rho-kinase increased this phosphorylation in COS-7 cells. Addition of thrombin to cultured human umbilical vein endothelial cells induced phosphorylation of eNOS at Thr495. Treatment with Y27632, a Rho-kinase inhibitor, suppressed thrombin-induced phosphorylation at Thr495. These results indicate that Rho-kinase can directly phosphorylate eNOS at Thr495 to suppress NO production in endothelium.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbrc.2007.07.030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Circulating extracellular microvesicles associated with electronic cigarette use increase endothelial cell inflammation and reduce nitric oxide production.
Exp Physiol
September 2024
Department of Integrative Physiology, University of Colorado, Boulder, Colorado, USA.
The purpose of this study was to determine the effect of circulating microvesicles isolated from chronic electronic (e-)cigarette users on cultured human umbilical vein endothelial cell (HUVEC) expression of nuclear factor-κB (NF-κB), cellular cytokine release, phosphorylation of endothelial nitric oxide synthase (eNOS) and NO production. The HUVECs were treated with microvesicles isolated via flow cytometry from nine non-tobacco users (five male and four female; 22 ± 2 years of age) and 10 e-cigarette users (six male and four female; 22 ± 2 years of age). Microvesicles from e-cigarette users induced significantly greater release of interleukin-6 (183.
View Article and Find Full Text PDFProstacyclin Synthase Deficiency Leads to Exacerbation or Occurrence of Endothelium-Dependent Contraction and Causes Cardiovascular Disorders Mainly via the Non-TxA Prostanoids/TP Axis.
Circ Res
August 2024
Cardiovascular Research Center (J.G., Yingbi Zhou, K.X., J.L., X.C., G.Y., X.S., Y.X., D.H., B.L.), Shantou University Medical College, China.
Article Synopsis
- - Prostaglandin I, produced by COX in endothelial cells, can cause vasodilation in some blood vessels while paradoxically leading to endothelium-dependent constriction (EDC) in others, particularly in diseases like hypertension, though the effects of PGIS deficiency on EDC and related cardiovascular issues are not well understood.
- - The study utilized various mouse models, including wild-type and genetically modified knockouts, to measure the impact of PGIS deficiency and assess vasomotor responses, indicating alterations in nitric oxide production and signaling.
- - Results showed that PGIS deficiency worsened EDC and led to increases in blood pressure and cardiac issues over time, but additional removal of the thromboxane receptor improved vascular function and reduced
Lipid Emulsions Inhibit Labetalol-Induced Vasodilation in the Isolated Rat Aorta.
Int J Mol Sci
June 2024
Institute of Medical Science, Gyeongsang National University, Jinju-si 52727, Gyeongsangnam-do, Republic of Korea.
Article Synopsis
- Lipid emulsions are explored for their potential to counteract cardiovascular issues caused by excessive labetalol, indicating their role as therapeutic agents against drug toxicity.
- The study found that the presence of intact endothelial cells enhances labetalol-induced vasodilation, while lipid emulsions significantly decrease this effect, regardless of endothelial presence.
- The mechanisms behind this inhibition include reducing cyclic guanosine monophosphate (cGMP) levels, modulating endothelial nitric oxide synthase (eNOS) activity, and lowering the concentration of labetalol itself.
LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Ameliorates Endothelial Dysfunction in Diabetic C57BL/6 Mice.
J Atheroscler Thromb
September 2024
Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences.
Article Synopsis
- LCZ696 (sacubitril/valsartan) has cardioprotective effects and may improve endothelial function in diabetes, which needs further investigation.
- In a study on diabetic mice, both LCZ696 and valsartan lowered blood pressure and improved endothelium-dependent vascular relaxation, but only LCZ696 enhanced eNOS and Akt phosphorylation.
- The results indicate that LCZ696 improves diabetes-induced endothelial dysfunction by increasing atrial natriuretic peptide bioavailability, suggesting it may be more effective than valsartan for vascular protection in diabetes.
Protecting cardiomyocytes from hypoxia-reoxygenation injury, empaglifozin and liraglutide alone or in combination?
J Basic Clin Physiol Pharmacol
January 2024
Department of Pharmaceutical Sciences, 8515 University of Saint Joseph, West Hartford, CT, USA.
Objectives: Empagliflozin, a sodium-dependent glucose co-transporter 2 (SGLT2) inhibitor, and liraglutide, a GLP-1 receptor (GLP-1R) agonist, are commonly recognized for their cardiovascular benefits in individuals with type 2 diabetes (T2D). In prior studies, we have demonstrated that both drugs, alone or in combination, were able to protect cardiomyocytes from injury induced by diabetes. Mechanistic investigations also suggested that the cardioprotective effect may be independent of diabetes In this study, we utilized a hypoxia-reoxygenation (H/R) model to investigate the cardiovascular benefits of SGLT2 inhibitor empagliflozin and GLP-1 receptor (GLP-1R) agonist liraglutide, both alone and in combination, in the absence of T2D.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!